Literature DB >> 28967482

Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.

Christopher G Pelligra1, Kejal Parikh2, Shien Guo3, Conor Chandler3, Jorge Mouro2, Safiya Abouzaid2, Sikander Ailawadhi4.   

Abstract

PURPOSE: Pomalidomide plus low-dose dexamethasone (POM-d), daratumumab monotherapy (DARA), and carfilzomib monotherapy (CAR) have been approved for use in the treatment of patients with heavily pretreated relapsed-refractory multiple myeloma (RRMM) in the US, based on findings from the MM-002, SIRIUS, and PX-171-003-A1 studies, respectively. The objective of this study was to assess the cost-effectiveness of POM-d, DARA, and CAR in this patient population from a US payer's perspective.
METHODS: A cost-effectiveness model was developed to estimate the cost and health outcomes over a 3-year time horizon in 3 health states: progression-free, post-progression, and death. The main efficacy data source was a matching-adjusted indirect comparison using data from the aforementioned studies. Direct medical costs were considered, including: treatment acquisition and administration (initial line and subsequent line), pre- and post-medication, prophylaxis treatment, adverse event management, and health care resource utilization. Sensitivity analyses were conducted. A scenario analysis that assumed equal efficacy across all 3 treatments was conducted. Costs, life-years, and quality-adjusted life-years were estimated and discounted at 3% per annum.
FINDINGS: Over 3 years, the use of POM-d was associated with similar life-years and quality-adjusted life-years gained compared with DARA and CAR (incremental: life-years, +0.02 and +0.07, respectively; quality-adjusted life-years, +0.01 and +0.05), and with a cost less than that of DARA (-$8,919) and similar to that of CAR (-$195). Sensitivity analyses illustrated that the results were sensitive to progression-free survival, treatment duration, and drug costs. An equal efficacy scenario resulted in cost-savings relative to those of both DARA and CAR (-$11,779 and -$12,595). IMPLICATIONS: POM-d may be a cost-effective treatment option relative to DARA or CAR in heavily pretreated patients with RRMM in the US.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cost effectiveness; economic models; immunomodulation; immunotherapy; multiple myeloma

Mesh:

Substances:

Year:  2017        PMID: 28967482     DOI: 10.1016/j.clinthera.2017.08.010

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  10 in total

1.  Cost Effectiveness of Transplant, Conventional Chemotherapy, and Novel Agents in Multiple Myeloma: A Systematic Review.

Authors:  Shuangshuang Fu; Chi-Fang Wu; Michael Wang; David R Lairson
Journal:  Pharmacoeconomics       Date:  2019-12       Impact factor: 4.981

2.  Cost-Effectiveness of Post-Autotransplant Lenalidomide in Persons with Multiple Myeloma.

Authors:  Monia Marchetti; Robert Peter Gale; Giovanni Barosi
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-05-01       Impact factor: 2.576

3.  Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).

Authors:  Ho Sup Lee; Kihyun Kim; Seok Jin Kim; Je-Jung Lee; Inho Kim; Jin Seok Kim; Hyeon-Seok Eom; Dok Hyun Yoon; Cheolwon Suh; Ho-Jin Shin; Yeung-Chul Mun; Min Kyoung Kim; Sung-Nam Lim; Chul Won Choi; Hye Jin Kang; Sung-Soo Yoon; Chang-Ki Min
Journal:  Am J Hematol       Date:  2020-01-24       Impact factor: 10.047

4.  Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma.

Authors:  Yaohua Cao; Lina Zhao; Tiantian Zhang; Weiling Cao
Journal:  Front Pharmacol       Date:  2021-03-01       Impact factor: 5.810

5.  Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma.

Authors:  Hedwig M Blommestein; Margreet G Franken; Chrissy H Y van Beurden-Tan; Nicole M A Blijlevens; Peter C Huijgens; Pieter Sonneveld; Carin A Uyl-de Groot; Sonja Zweegman
Journal:  JAMA Netw Open       Date:  2021-03-01

6.  Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.

Authors:  Anshul Shah; Jonathan C Tosh; Apoorva Ambavane; Andreas Nikolaou; Cosmina Hogea; Yevgeniy Samyshkin; Boris Gorsh; Eric M Maiese; Feng Wang
Journal:  Clinicoecon Outcomes Res       Date:  2021-09-10

7.  The Cost of Enfortumab Vedotin Wastage Due to Vial Size-A Real-World Analysis.

Authors:  Michal Sarfaty; Assaf Moore; Ashley M Regazzi; Aaron P Mitchell; Jonathan E Rosenberg
Journal:  Cancers (Basel)       Date:  2021-11-27       Impact factor: 6.639

8.  Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer.

Authors:  Miriam Kimpton; Srishti Kumar; Philip S Wells; Doug Coyle; Marc Carrier; Kednapa Thavorn
Journal:  CMAJ       Date:  2021-10-12       Impact factor: 8.262

9.  US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma.

Authors:  Mike Dolph; Gabriel Tremblay; Hoyee Leong
Journal:  Clinicoecon Outcomes Res       Date:  2021-06-10

10.  Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.

Authors:  Michael Dolph; Gabriel Tremblay; Hoyee Leong
Journal:  Pharmacoeconomics       Date:  2021-08-09       Impact factor: 4.981

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.